1610 - Clostridium botulinum type A toxin-haemagglutin complex (Dysport) for the treatment of moderate to severe upper-limb spasticity due to cerebral palsy

Page last updated: 13 October 2020

Application Detail

Description of Medical Service

Injection of Clostridium Botulinum Type A Toxin-Haemagglutinin Complex (Dysport) for the treatment of patients aged 2 years and older for upper limb spasticity associated with cerebral palsy.

Description of Medical Condition

Spasticity is a chronic condition causing deformity and pain, and occurs in approximately 91% of children with cerebral palsy. Upper limb spasticity causes reduced motor function and reduced muscle strength. Spasticity is characterised by an increase in muscle tone that leads to spasms and ultimately muscle and soft tissue contracture. Contractures can eventually render the limb functionless.

Reason for Application

The applicant seeks to change the descriptor of MBS item 18361 to include 'Clostridium Botulinum Type A Toxin-Haemagglutinin Complex (Dysport)' in the list of botulinum toxins associated with the item number. The request seeks to align the descriptor with recent changes to the wording for patients aged 2 years and older with upper limb spasticity associated with cerebral palsy, and also align the descriptor for MBS item 18361 with the PBS criteria by removing the requirement that adult cerebral palsy patients must have commenced treatment with botulinum toxin as a paediatric patient.

Medical Service Type


Previous Application Number/s

Not Applicable

Associated Documentation

Application Form


Consultation Survey


PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 725 KB)
Public Summary Document (Word 229 KB)

Meetings for this Application






28-29 July 2020